
Steve G. Geis, MD, PhD
Advertisement
Articles by Steve G. Geis, MD, PhD

Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5